Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 10, Pages 2484-2492
Publisher
Oxford University Press (OUP)
Online
2013-07-13
DOI
10.1093/annonc/mdt239
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial
- (2013) F. C. Bidard et al. ANNALS OF ONCOLOGY
- Failure Patterns in Resected Pancreas Adenocarcinoma
- (2013) Jordan M. Winter et al. ANNALS OF SURGERY
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
- (2013) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
- (2013) Somnath Mukherjee et al. LANCET ONCOLOGY
- The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
- (2013) Thierry Conroy et al. Current Oncology Reports
- Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma
- (2012) J. B. Bachet et al. ANNALS OF ONCOLOGY
- A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
- (2012) Peter J Hosein et al. BMC CANCER
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
- (2012) Matthew H. G. Katz et al. CANCER
- Unresectable Locally Advanced Pancreatic Cancer: Treatment With Neoadjuvant Leucovorin, Fluorouracil, Irinotecan, and Oxaliplatin and Assessment of Surgical Resectability
- (2012) Esther Liu Mondo et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity
- (2012) Krishna S. Gunturu et al. MEDICAL ONCOLOGY
- Locally Advanced Pancreatic Cancer: Where Should We Go From Here?
- (2011) Philip Agop Philip JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation ofSmad4(Dpc4)Immunostaining With Pattern of Disease Progression
- (2011) Christopher H. Crane et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
- (2011) Patrick J. Loehrer et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer
- (2011) Jerome Martin Laurence et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment
- (2011) Shinichiro Takahashi et al. Journal of Hepato-Biliary-Pancreatic Sciences
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: A meta-analysis
- (2011) Chang-Peng Zhu et al. RADIOTHERAPY AND ONCOLOGY
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
- (2010) Sonja Gillen et al. PLOS MEDICINE
- A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer
- (2009) Alessio G. Morganti et al. ANNALS OF SURGICAL ONCOLOGY
- Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement
- (2009) Ross A. Abrams et al. ANNALS OF SURGICAL ONCOLOGY
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
- (2009) Mark P. Callery et al. ANNALS OF SURGICAL ONCOLOGY
- Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review
- (2009) Florence Huguet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
- (2009) Christine A. Iacobuzio-Donahue et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
- (2008) B. Chauffert et al. ANNALS OF ONCOLOGY
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
- (2008) Matthew H.G. Katz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started